NCT05854069

Brief Summary

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for not_applicable

Timeline
12mo left

Started Apr 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Apr 2023Apr 2027

First Submitted

Initial submission to the registry

April 24, 2023

Completed
6 days until next milestone

Study Start

First participant enrolled

April 30, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 11, 2023

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2027

Last Updated

October 29, 2025

Status Verified

October 1, 2025

Enrollment Period

3.8 years

First QC Date

April 24, 2023

Last Update Submit

October 27, 2025

Conditions

Keywords

Continuous glucose monitorSocial supportGoal settingDiabetes distressHemoglobin A1cTime in rangeEmerging adultsFamily supportText messageMobile health

Outcome Measures

Primary Outcomes (3)

  • CGM frequency of use during the intervention period

    Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

    Baseline and 6 months post-baseline

  • CGM frequency of use during the intervention period

    Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

    Baseline and 6 months post-baseline

  • Gaps in CGM use

    Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

    6 months post-baseline

Secondary Outcomes (4)

  • CGM behavioral responses during the intervention period

    Baseline and 6 months post-baseline

  • Barriers to CGM use during the intervention period

    Baseline and 6 months post-baseline

  • Barriers to CGM use during the intervention period

    Baseline and 6 months post-baseline

  • CGM satisfaction during the intervention period

    Baseline and 6 months post-baseline

Other Outcomes (2)

  • Data sharing during the intervention period

    6 months post-baseline

  • Satisfaction with data-sharing relationships

    6 months post-baseline

Study Arms (2)

FAMS-T1D

EXPERIMENTAL

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Behavioral: FAMS-T1DBehavioral: Digital resources for diabetes

Digital resources for diabetes

PLACEBO COMPARATOR

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Behavioral: Digital resources for diabetes

Interventions

FAMS-T1DBEHAVIORAL

FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

Also known as: Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes
FAMS-T1D

Quality digital resources about diabetes management provided upon enrollment and during the study.

Digital resources for diabetesFAMS-T1D

Eligibility Criteria

Age18 Years - 24 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • PERSONS WITH DIABETES
  • Ages 18-24
  • Have a diagnosis of T1D and has been taking insulin for at least one year
  • Comfortable sending and receiving texts
  • Can speak, read, and write in English
  • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
  • Using a continuous glucose monitor (CGM)
  • SUPPORT PERSONS
  • Age 18 or older
  • Can speak, read, and write in English or Spanish
  • Comfortable sending and receiving texts

You may not qualify if:

  • PERSONS WITH DIABETES
  • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
  • Plans to live outside the country during the study period
  • SUPPORT PERSONS
  • Shares a phone with the person with diabetes
  • Plans to live outside of the country during the study period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Children's Hospital of Los Angeles

Los Angeles, California, 90027, United States

Location

University of Utah

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

April 24, 2023

First Posted

May 11, 2023

Study Start

April 30, 2023

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

April 30, 2027

Last Updated

October 29, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share

After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.
Access Criteria
Contact the principal investigator

Locations